MyChesCo on MSN

Medicus submits phase 2 study design for Teverelix to FDA

PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S.
Seeking Alpha

Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301

LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company’s proposed single ...
pharmaphorum

From preclinical toxicology to clinical safety: The path for oncology IND submissions

Preserve study integrity. Resist the temptation to bolt new exploratory endpoints midstream. If an additional endpoint is ...
PharmExec

Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB

Incorporating patient voice early can reduce burden through fewer visits, simpler procedures, and selective decentralization while maintaining trial objectives. Engagement failures commonly stem from ...
Mirage News

Training Next Generation Of Clinical Trial Leaders

Clinical trials are the engine of modern cancer care, transforming scientific discoveries into new treatments that can save ...

PointClickCare Launches Study Buddy, the First AI-Powered Research Platform to Deliver Instant, Grant Submission-Ready Evidence from Long-Term Care Data

PointClickCare, a leading health tech company helping providers deliver exceptional care, today announced the launch of Study ...
Seeking Alpha

Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

“We are particularly gratified to reach concurrence with the FDA on the overall study design, endpoints, and patient populations,” said Aridis CEO Vu Truong. “This provides a clear clinical and ...